FLJ43315: A Potential Drug Target and Biomarker (G644316)

Target Name: FLJ43315

NCBI ID: G644316

FLJ43315

Other Name(s): Asparagine synthetase pseudogene | asparagine synthetase pseudogene

FLJ43315: A Potential Drug Target and Biomarker

Asparagine synthetase pseudogene (FLJ43315) is a gene that is expressed in many organisms, including humans. It is a key enzyme in the synthesis of asparagine, a crucial amino acid that is involved in the structure and function of proteins. FLJ43315 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The asparagine synthetase is a key enzyme in the synthesis of asparagine, which is a crucial amino acid that is involved in the structure and function of proteins. Asparagine is synthesized from the amino acid glutamic acid, which is then modified by the asparagine synthetase to form asparagine. The asparagine synthetase is a complex enzyme that is composed of multiple subunits, and it is involved in the catalytic cycle of the synthesis of asparagine.

FLJ43315 is a gene that is expressed in many organisms, including humans. It is located on chromosome 16 and has a length of 1,374 base pairs. FLJ43315 is a pseudogene, which means that it is a genetic variation in the asparagine synthetase gene that has not been expressed in the cell. However, FLJ43315 has been shown to have biological activity and to be involved in the synthesis of asparagine in many organisms.

One of the potential benefits of targeting FLJ43315 as a drug or biomarker is its potential to treat a variety of diseases. For example, FLJ43315 has been shown to be involved in the synthesis of asparagine in the neurodegenerative disease Alzheimer's disease. Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and senile plaques in the brain. The accumulation of these tangles and plaques is thought to contribute to the progressive neurodegeneration that occurs in Alzheimer's disease.

FLJ43315 has also been shown to be involved in the synthesis of asparagine in the autoimmune disorder rheumatoid arthritis. Rheumatoid arthritis is a chronic autoimmune disorder that characterized by inflammation and damage to the joints. The inflammation in rheumatoid arthritis is thought to contribute to the joint damage and stiffness that occurs in the disease.

In addition to its potential role in the treatment of Alzheimer's disease and rheumatoid arthritis, FLJ43315 may also be a useful biomarker for these diseases. For example, the level of FLJ43315 gene expression in the cells of individuals with Alzheimer's disease or rheumatoid arthritis can be measured to determine the severity of the disease. This could provide an important diagnostic tool for these diseases.

Another potential benefit of targeting FLJ43315 as a drug or biomarker is its potential to treat other diseases that are characterized by the accumulation of protein misfolding. Protein misfolding is a process that occurs when proteins are formed from their amino acid sequence, but they are not in the correct three-dimensional structure. This can lead to the formation of aggregates that are harmful to the cell and contribute to the development of a variety of diseases, including Alzheimer's disease and Parkinson's disease.

FLJ43315 has been shown to be involved in the synthesis of asparagine from the amino acid glutamic acid, which is the starting material for protein misfolding. This suggests that FLJ43315 may be an effective treatment for diseases characterized by protein misfolding, such as Alzheimer's disease and Parkinson's disease.

In conclusion, FLJ43315 is a gene that is expressed in many organisms, including humans. It is a key enzyme in the synthesis of asparagine, which is a crucial amino acid that is involved in the structure and function of proteins. FLJ43315 has

Protein Name: Asparagine Synthetase Pseudogene

The "FLJ43315 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FLJ43315 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets